시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 악성 빈혈 진단 및 치료 시장 보고서(2025년)
Pernicious Anemia Diagnosis And Treatment Global Market Report 2025
상품코드 : 1760674
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,290,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,091,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,893,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

악성 빈혈 진단 및 치료 시장 규모는 향후 몇 년간 강한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 원격의료 서비스의 확대, 조기 진단에 대한 수요 증가, 맞춤형 의료에 대한 관심 증가, 정부 검진 프로그램, 비침습적 치료에 대한 환자 선호도 증가 등에 기인합니다. 예측 기간의 주요 동향으로는 장기간 작용형 비타민 B12 제제의 개발, 가정용 진단 키트의 사용 증가, 빈혈 진단에 인공 지능(AI)의 통합, 디지털 건강 모니터링 도구의 부상, 진단 기술의 발전 등이 있습니다.

비타민 B12 결핍의 유병률 증가가 향후 몇 년간 악성 빈혈 진단 및 치료 시장 성장을 촉진할 것으로 예상됩니다. 비타민 B12 결핍은 신체에 충분한 양의 비타민이 부족해 적혈구를 충분히 생성하지 못해 피로, 약화, 신경학적 문제 등 증상을 유발합니다. 비타민 B12 결핍의 유병률은 식물성 식단의 확산으로 인해 증가하고 있습니다. 식물성 식단은 자연적인 비타민 B12 공급원이 부족하며, 적절한 보충 없이 섭취량이 부족할 수 있습니다. 이 결핍은 악성 빈혈 진단 및 치료의 필요성을 뒷받침합니다. 비타민 B12 수치가 낮으면 적혈구 생성이 직접적으로 방해받기 때문에, 의사들은 비타민 B12 보충제를 주요하고 효과적인 치료 방법으로 처방합니다. 예를 들어, 2023년 2월 영국 국민보건서비스(NHS) 보고서에 따르면 비타민 B12와 엽산 결핍은 노인층에서 더 흔하며, 75세 이상 인구 중 약 10명 중 1명, 65세에서 74세 사이 인구 중 약 20명 중 1명이 영향을 받습니다. 따라서 비타민 B12 결핍의 증가하는 유병률은 악성 빈혈 진단 및 치료 시장 성장에 기여하고 있습니다.

악성 빈혈 진단 및 치료 시장 선도 기업들은 환자 순응도를 개선하고 장기적인 질환 관리를 위해 비타민 B12 유지 요법과 같은 혁신적인 솔루션 개발에 집중하고 있습니다. 비타민 B12 유지 요법은 구강 정제, 주사, 또는 비강 스프레이를 통해 정기적이고 지속적인 보충을 통해 적정 수준의 B12를 유지하고 결핍 관련 증상의 재발을 예방하는 것을 포함합니다. 예를 들어, 2024년 2월 인도에 본사를 두고 있는 제약 회사인 루핀 제약(Lupin Pharmaceuticals Inc.)은 비타민 B12 보충을 위한 비침습적 대안으로 시아노코발라민 비강 스프레이(500 mcg/스프레이)를 출시했습니다. 이 비강 스프레이는 구강 비타민 B12 제형 사용에 어려움을 겪는 악성 빈혈 환자에게 편리하고 효과적인 옵션을 제공합니다. 이는 비타민 B12 흡수율을 향상시키고 비타민 B12 결핍 관리에 도움을 주어 환자의 치료 순응도를 높이고 치료 결과를 개선합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Pernicious anemia diagnosis and treatment refers to the process of identifying and managing a condition where the body is unable to produce sufficient healthy red blood cells due to impaired absorption of vitamin B12, often due to a lack of intrinsic factor. The diagnosis involves evaluating clinical symptoms such as fatigue, weakness, and neurological issues. Treatment aims to restore vitamin B12 levels, promote normal red blood cell production, alleviate symptoms, and prevent long-term health complications.

The primary types of pernicious anemia diagnosis and treatment include complete blood count (CBC) tests, vitamin B12 deficiency tests, and intrinsic factor deficiency tests. A CBC test is a common blood test that measures various blood components, helping to identify abnormal levels of red blood cells and hemoglobin, which can indicate anemia and assist in diagnosing the condition. Treatments vary and include vitamin B12 injections, oral vitamin B12 pills, and intranasal sprays, all of which are administered via different routes such as injection, oral, and intranasal. These treatments are utilized by end users, including hospitals, clinics, diagnostic centers, and other healthcare settings.

The pernicious anemia diagnosis and treatment market research report is one of a series of new reports from The Business Research Company that provides pernicious anemia diagnosis and treatment market statistics, including the pernicious anemia diagnosis and treatment industry's global market size, regional shares, competitors with an pernicious anemia diagnosis and treatment market share, detailed pernicious anemia diagnosis and treatment market segments, market trends and opportunities, and any further data you may need to thrive in the pernicious anemia diagnosis and treatment industry. This pernicious anemia diagnosis and treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pernicious anemia diagnosis and treatment market size has grown strongly in recent years. It will grow from $1.42 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to rising awareness of vitamin B12 deficiency, the increasing prevalence of autoimmune disorders, the growing geriatric population, enhanced physician education on anemia, and the availability of both oral and injectable vitamin B12 treatments.

The pernicious anemia diagnosis and treatment market size is expected to see strong growth in the next few years. It will grow to $1.97 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth during the forecast period can be attributed to the expansion of telemedicine services, increasing demand for early diagnosis, a growing focus on personalized medicine, government screening initiatives, and a rising patient preference for non-invasive treatments. Key trends in the forecast period include the development of long-acting vitamin B12 formulations, a growing use of home-based diagnostic kits, the integration of artificial intelligence (AI) in anemia detection, the rise of digital health monitoring tools, and advancements in diagnostic technologies.

The increasing prevalence of vitamin B12 deficiency is expected to fuel growth in the pernicious anemia diagnosis and treatment market in the coming years. Vitamin B12 deficiency occurs when the body lacks sufficient amounts of the vitamin to produce enough red blood cells, leading to symptoms such as fatigue, weakness, and neurological issues. The prevalence of vitamin B12 deficiency is rising due to the growing adoption of plant-based diets, which often lack adequate natural sources of B12 and may result in insufficient intake without proper supplementation. This deficiency supports the need for pernicious anemia diagnosis and treatment, as low B12 levels directly hinder red blood cell production, prompting doctors to administer B12 supplementation as a primary and effective treatment approach. For example, in February 2023, a report by the National Health Service (NHS) indicated that both vitamin B12 and folate deficiencies are more common among older adults, affecting approximately 1 in 10 individuals aged 75 or older and 1 in 20 of those aged 65 to 74. Therefore, the rising prevalence of vitamin B12 deficiency is contributing to the growth of the pernicious anemia diagnosis and treatment market.

Leading companies in the pernicious anemia diagnosis and treatment market are focusing on developing innovative solutions, such as vitamin B12 maintenance therapy, to improve patient adherence and long-term disease management. Vitamin B12 maintenance therapy involves regular, ongoing supplementation through oral tablets, injections, or nasal sprays to maintain adequate B12 levels and prevent the recurrence of deficiency-related symptoms. For example, in February 2024, Lupin Pharmaceuticals Inc., a pharmaceutical company based in India, launched a cyanocobalamin nasal spray (500 mcg/spray) as a non-invasive alternative for vitamin B12 supplementation. This nasal spray offers a convenient and effective option for patients with pernicious anemia who face challenges with oral vitamin B12 forms. It enhances B12 absorption and supports the management of vitamin B12 deficiency, ultimately improving patient compliance and treatment outcomes.

In February 2025, Lightstone Group, a U.S.-based investment firm, acquired Pfizer's Durham facility for $41.1 million. This acquisition enabled the firm to add a move-in-ready, state-of-the-art clinical supply cGMP facility, built to meet the highest quality standards, to its growing portfolio. Pfizer Inc., a U.S.-based manufacturer, produces vitamin B12 capsules for pernicious anemia treatment.

Major players in the pernicious anemia diagnosis and treatment market are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, Thermo Fisher Scientific Inc., GSK plc, Takeda Pharmaceutical Company Limited, Lupin Limited, Eli Lilly and Company, Amgen Inc., DSM Nutritional Products AG, Bio-Rad Laboratories Inc., CSL Vifor Pharma, Daiichi Sankyo Co. Ltd., Par Pharmaceutical Companies Inc., AdvaCare Pharma, and Monobind Inc.

North America was the largest region in the pernicious anemia diagnosis and treatment market in 2024. The regions covered in pernicious anemia diagnosis and treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pernicious anemia diagnosis and treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pernicious anemia diagnosis and treatment market consists of revenues earned by entities by providing services such as antibody testing, neurological evaluation services, nutritional counseling, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The pernicious anemia diagnosis and treatment market also includes sales of methylcobalamin supplements, combination supplements, and anemia management trackers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pernicious Anemia Diagnosis And Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pernicious anemia diagnosis and treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pernicious anemia diagnosis and treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pernicious anemia diagnosis and treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Pernicious Anemia Diagnosis And Treatment Market Characteristics

3. Pernicious Anemia Diagnosis And Treatment Market Trends And Strategies

4. Pernicious Anemia Diagnosis And Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pernicious Anemia Diagnosis And Treatment Growth Analysis And Strategic Analysis Framework

6. Pernicious Anemia Diagnosis And Treatment Market Segmentation

7. Pernicious Anemia Diagnosis And Treatment Market Regional And Country Analysis

8. Asia-Pacific Pernicious Anemia Diagnosis And Treatment Market

9. China Pernicious Anemia Diagnosis And Treatment Market

10. India Pernicious Anemia Diagnosis And Treatment Market

11. Japan Pernicious Anemia Diagnosis And Treatment Market

12. Australia Pernicious Anemia Diagnosis And Treatment Market

13. Indonesia Pernicious Anemia Diagnosis And Treatment Market

14. South Korea Pernicious Anemia Diagnosis And Treatment Market

15. Western Europe Pernicious Anemia Diagnosis And Treatment Market

16. UK Pernicious Anemia Diagnosis And Treatment Market

17. Germany Pernicious Anemia Diagnosis And Treatment Market

18. France Pernicious Anemia Diagnosis And Treatment Market

19. Italy Pernicious Anemia Diagnosis And Treatment Market

20. Spain Pernicious Anemia Diagnosis And Treatment Market

21. Eastern Europe Pernicious Anemia Diagnosis And Treatment Market

22. Russia Pernicious Anemia Diagnosis And Treatment Market

23. North America Pernicious Anemia Diagnosis And Treatment Market

24. USA Pernicious Anemia Diagnosis And Treatment Market

25. Canada Pernicious Anemia Diagnosis And Treatment Market

26. South America Pernicious Anemia Diagnosis And Treatment Market

27. Brazil Pernicious Anemia Diagnosis And Treatment Market

28. Middle East Pernicious Anemia Diagnosis And Treatment Market

29. Africa Pernicious Anemia Diagnosis And Treatment Market

30. Pernicious Anemia Diagnosis And Treatment Market Competitive Landscape And Company Profiles

31. Pernicious Anemia Diagnosis And Treatment Market Other Major And Innovative Companies

32. Global Pernicious Anemia Diagnosis And Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pernicious Anemia Diagnosis And Treatment Market

34. Recent Developments In The Pernicious Anemia Diagnosis And Treatment Market

35. Pernicious Anemia Diagnosis And Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기